LCD-L39644
Document details
Summary
The introduction of the Intraosseous Basivertebral Nerve Ablation LCD by Noridian may result in increased billing opportunities for eligible procedures starting January 28, 2024. Providers should ensuNew billing opportunities for nerve ablation procedures!
Affected codes
ICD-10-CM
Affected specialty
Pain Management alerts →Source document
https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=39644&ver=12CLV Intelligence summarizes publicly available federal publications. Not affiliated with or endorsed by any government agency.
Related alerts
4Policy FDA-NDA005010 · Pain Management
The billing pathway for DEMEROL cannot be determined until the FDA label publishes further details regarding its billing status. Billing teams should verify against the FDA label for updated informati
View alertPolicy FDA-NDA011483 · Pain Management
The billing impact of SYNALGOS-DC will be classified under Part D due to its oral route of administration. Billing teams should verify the FDA label for precise billing details as they become availabl
View alertPolicy FDA-NDA022304 · Pain Management
The drug tapentadol hydrochloride is administered orally and is classified under Part D of Medicare billing. Billing teams should verify against the FDA label for any specific billing details once pub
View alertPolicy FDA-NDA202080 · Pain Management
As OXAYDO is administered orally in tablet form, it will be billed under Part D. The exact billing details may vary, so billing teams should verify the payment methodology once the FDA label is publis
View alert